tiprankstipranks
Analyst Profile
Followed by 4 other investors
.
Nicholas Keher

Nicholas Keher

RBC Capital
Wall Street Analyst
Ranked #7,762 out of 8,045 Analysts on TipRanks (#20,641 out of 21,519 overall experts)

Success Rate

38%
20 out of 52 Profitable Transactions

Average Return

-17.00%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Nicholas Keher's ratings since 2014 and opened each position for the duration of 1 Year:
38.46% of your transactions would have been profitable with an average return of -17.0%

Stock Rating Distribution

103Ratings
48.54% Buy
44.66% Hold
6.80% Sell
Distribution of Nicholas Keher's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United KingdomUK Market
United StatesUS Market
CanadaCanadian Market

Best Rating

Stock:
BioCryst Pharmaceuticals
(BCRX)
Rating Type:Buy
Dates:Jan 02, 2018 - Jan 02, 2019
Gain:56.20%
The most profitable rating made by Nicholas Keher

Nicholas Keher's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Smith & Nephew Snats
Oct 13, 2014
Hold
Downgraded
0%
-6.60%
3
Shield Therapeutics
Aug 08, 2016
Buy
Reiterated
18,137.90p
(208982.42% Upside)
0%
0.00%
1
SPH
Sinclair Pharma
Apr 11, 2017
Buy
Reiterated
67%
-12.17%
3
TSTIF
TSO3 Inc
Sep 01, 2017
Buy
Reiterated
0%
-74.80%
1
Opsens Inc
Oct 02, 2017
Buy
Reiterated
C$2.56
(-3.57% Downside)
0%
-27.20%
2
Intuitive Surgical
Nov 02, 2017
Hold
Reiterated
$350.00
(46.90% Upside)
0.00%
1
Charles River Labs
Nov 02, 2017
Hold
Reiterated
$110.00
(-52.56% Downside)
0.00%
1
ObsEva SA
Nov 02, 2017
Buy
Reiterated
$22.00
(7825.07% Upside)
100%
+45.70%
1
Abeona Therapeutics
Nov 02, 2017
Buy
Reiterated
$23.00
(394.62% Upside)
0%
-44.80%
1
Akebia Therapeutics
Nov 02, 2017
Hold
Reiterated
$17.00
(4005.29% Upside)
0.00%
1
List of latest recommendations made by Nicholas Keher. Click to expand and see Nicholas Keher's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More